New Jersey Court Rules HRT Labeling Adequate as a Matter of Law

July 01, 2008
The mass tort judge handling hormone replacement cases in New Jersey recently dismissed failure to warn claims against Wyeth and Upjohn, ruling that the plaintiffs had not overcome the presumption of adequacy of FDA-approved labels created by the New Jersey Products Liability Act. The decision could have a significant impact on other drug failure to warn claims governed by New Jersey law.